semaglutide and cholecystitis GLP-1 receptor agonists gallbladder disease risk: insights into molecular mechanisms and clinical implications ACG 2023 Annual Meeting Posters

10.1093/ckj/sfv148 104 VernetD.FerriniM

ADP = adenosine diphosphate

Inclusion of GLP-1 agonists regardless of history of obesity reduced HRs and narrowed CIs but did not change the significance of the results (Table 2)

raisa akter (verified purchase) Rated 5 out of 5 This is my second order

A dose-dependent response has been observed with half (125 mg), normal (250 mg), and double (500 mg) doses, with higher doses producing greater blood sugar blunting effects

Overall, the results of the meta-analysis have shown that people with metabolic syndrome have 8.2% more uric acid, leading the authors to speculate that reducing urate levels could positively impact the development of this syndrome